Related Experiment Video
Updated: Apr 18, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
13.0K
Therapeutic interference with leukocyte recirculation in multiple sclerosis
1Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
European Journal of Neurology
|January 14, 2015
Summary
Natalizumab and fingolimod effectively reduce multiple sclerosis (MS) relapses by blocking immune cell migration. These therapies are safe for most patients but are typically reserved for highly active MS due to potential serious side effects.
Area of Science:
- Neuroimmunology
- Pharmacology
Background:
- Multiple sclerosis (MS) is an immune-mediated condition causing CNS inflammation, demyelination, and axonal damage.
- T cells are implicated in initiating MS pathology.
- Reducing immune cell activation and recruitment can decrease MS disease activity.
Purpose of the Study:
- To review the mechanisms of action and treatment effects of natalizumab and fingolimod in MS.
- To compare how these therapies interfere with immune cell recruitment.
Main Methods:
- Review of existing literature on natalizumab and fingolimod in MS.
- Analysis of their molecular targets and clinical outcomes.
Main Results:
- Fingolimod inhibits lymphocyte egress from lymph nodes via S1P receptor 1 antagonism.
- Natalizumab blocks lymphocyte migration to the CNS by targeting α4 integrin.
- Both treatments demonstrate efficacy in reducing relapses, disability progression, and MRI-detected disease activity.
- Both therapies are generally safe and well-tolerated, though serious side effects necessitate cautious use.
Conclusions:
- Natalizumab and fingolimod are effective in managing relapsing-remitting MS by modulating immune cell migration.
- Their primary mechanisms involve distinct pathways affecting immune cell trafficking.
- Further research is needed to fully elucidate additional effects within the CNS and on other immune cells, as well as long-term disease progression impacts.
Related Concept Videos
01:24T Cell Types and Functions
3.5K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.5K
01:19Multiple Sclerosis l: Introduction
2
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
2